Cargando…
T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
Autores principales: | Cemerski, Saso, Zhao, Shuxia, Chenard, Melissa, Laskey, Jason, Cui, Long, Shukla, Rinkan, Haines, Brian, Hsieh, Edward, Beaumont, Maribel, Mattson, Jeanine, Blumenschein, Wendy, Hirsch, Heather, Fayadat-Dilman, Laurence, Liang, Linda, De Waal Malefyt, Rene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649371/ http://dx.doi.org/10.1186/2051-1426-3-S2-P183 |
Ejemplares similares
-
Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023) -
LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020) -
Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021) -
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021) -
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)